Ultime notizie per Silk Energy (OTC:SLKEF) Azioni

Silk Energy Ltd is a canada based company engaged in the acquisition, exploration and development of mineral properties.

SILK ENERGY LTD COM by SILK ENERGY LTD COM

Silk Energy Ltd

Life360, Inc. ("Life360" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>, ASX: 360))), today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Life360 also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
Description of notes
The notes will be senior, unsecured obligations of Life360, will accrue interest payable semi-annually in arrears and will mature on June 1, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Life360 will settle conversions in cash or a combination of cash and shares of its common stock, at Life360's election.
The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Life360's option at any time, and from time to time, on or after June 5, 2028 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Life360's common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
If certain corporate events that constitute a "fundamental change" occur, then, subject to a limited exception, noteholders may require Life360 to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.
The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.
Use of proceeds
Life360 intends to use a portion of the net proceeds from the offering to fund the cost of entering into the capped call transactions. Life360 intends to use the remainder of the net proceeds from the offering for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses, products, services or technologies. If the initial purchasers exercise their option to purchase additional notes, then Life360 intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below.

News

Offerings

Life360 Plans $250M Convertible Notes Offering, Eyes Future Growth and Strategic Deals

BMO Capital analyst Katja Jancic upgrades Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Market Perform to Outperform and raises the price target from $140 to $145.

Upgrades

Price Target

Analyst Ratings

BMO Capital Upgrades Nucor to Outperform, Raises Price Target to $145

BMO Capital analyst Michael Zaremski initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Outperform rating and announces Price Target of $38.

Initiation

BMO Capital Initiates Coverage On Aspen Insurance Hldgs with Outperform Rating, Announces Price Target of $38

As Donald Trump&#8216;s administration nears completion of a proposal to ease big bank rules, Wall Street&#8217;s megabanks are largely expected to cheer the lower supplementary leverage ratio (SLR), allowing them to hold fewer capital reserves against their assets.
What Happened: Analysts largely agree that the Trump administration's push to ease big bank rules, particularly the SLR, is a boon for banks and could stimulate broader economic growth.
Gennadiy Goldberg, the head of U.S. rates strategy at TD Securities, <a href="https://www.politico.com/news/2025/05/31/trump-administration-prepares-to-ease-big-bank-rules-00377347">told </a>Politico that easing capital rules for the banks will free the capital to buy more U.S. Treasuries
However, Phillip Basil, Better Markets&#8217; director of economic growth and financial stability, told Politico that lowering big banks&#8217; capital requirements heightens financial stability risks, accusing the banking industry of exploiting recent Treasury market turmoil as a pretext to push for long-sought regulatory relief.
Meanwhile, Kepp Loeffler, the administrator of the U.S. Small Business Administration, said that Small businesses &#8220;can win with a level playing field – ESPECIALLY combined with tax cuts and deregulation.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Small businesses finally have a fighter in the White House who won't keep allowing unfair trade practices to crush their industries and outsource their jobs. They know they can win with a level playing field – ESPECIALLY combined with tax cuts and deregulation. <a href="https://t.co/APEVgiLIb6">pic.twitter.com/APEVgiLIb6</a>
&mdash; Kelly Loeffler (@SBA_Kelly) <a href="https://twitter.com/SBA_Kelly/status/1927856861576831355?ref_src=twsrc%5Etfw">May 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/news/politics/25/05/45691310/trump-tariff-uncertainty-enters-courts-experts-say-investors-should-expect-elevated-turbulence-amid-the-bullish-gridlock">Trump Tariff Uncertainty Enters Courts: Experts Say ‘Investors Should Expect Elevated Turbulence' Amid The Bullish ‘Gridlock'</a>
Why It Matters: Here a list of some banking stocks that investors could consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>Year-To-Date Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</td>
<td>-0.36%</td>
<td>10.66%</td>
</tr>
<tr>
<td>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</td>
<td>10.00%</td>
<td>30.81%</td>
</tr>
<tr>
<td>Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>4.43%</td>
<td>31.97%</td>
</tr>
<tr>
<td>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</td>
<td>2.60%</td>
<td>31.43%</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>7.69%</td>
<td>21.64%</td>
</tr>
<tr>
<td>Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td>6.54%</td>
<td>26.02%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>)</td>
<td>-9.44%</td>
<td>3.64%</td>
</tr>
<tr>
<td>Grupo Financiero Galicia SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGAL#NASDAQ">GGAL</a>)</td>
<td>-15.63%</td>
<td>63.06%</td>
</tr>
<tr>
<td>BancFirst Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>)</td>
<td>6.55%</td>
<td>46.67%</td>
</tr>
</tbody>
</table>
</figure>
Here are some banking exchange-traded funds to look out for.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>ETFs</td>
<td>Year-To-Date Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>Invesco KBW Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NASDAQ">KBWB</a>)</td>
<td>0.51%</td>
<td>22.70%</td>
</tr>
<tr>
<td>SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>)</td>
<td>-3.11%</td>
<td>16.44%</td>
</tr>
<tr>
<td>First Trust Nasdaq Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXO#NASDAQ">FTXO</a>)</td>
<td>-1.92%</td>
<td>17.65%</td>
</tr>
<tr>
<td>Themes Global Systemically Important Banks ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIB#NASDAQ">GSIB</a>)</td>
<td>25.20%</td>
<td>36.01%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Friday. The SPY was down 0.11% at $589.39, while the QQQ declined 0.16% to $519.11, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of the S&amp;P 500, Dow Jones and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45688628/dells-ai-server-orders-hit-record-12-1-billion-in-q1-backlog-swells-to-14-4-billion-exceptionally-strong-demand">Dell's AI Server Orders Hit Record $12.1 Billion In Q1, Backlog Swells To $14.4 Billion: ‘Exceptionally Strong Demand'Jim Cramer Attributes Nvidia's Premarket Dip To ‘Meme Money' Frenzy: ‘Just Small Motivated Shareholders Knocking It Down'</a></li>
</ul>
Photo courtesy: Shutterstock

BANF

FITB

FTXO

GGAL

GSIB

KBWB

Trump Administration Set To Ease Big Bank Rules In Major Rollback Since 2008 Crisis: Here Are The Stocks And ETFs Investors Could Consider

<ul>
<li>Real-world claims studies evaluating UZEDY&#xAE; (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options</li>
<li>Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date</li>
<li>As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia</li>
</ul>

TEVA

Reported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics

The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax&#xAE;), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.

MRNA

Reported Saturday, mNEXSPIKE Becomes FDA-Approved: Moderna's New COVID-19 Vaccine Shows Higher Efficacy vs. Spikevax In Phase 3 Trial

<ul>
<li>26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases</li>
<li>Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms</li>
<li>MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C (combination dose escalation) remains on treatment after more than 14 months</li>
<li>Combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events</li>
</ul>

Reported Saturday, Xilio's Tumor-Activated Anti-CTLA-4 Vilastobart Shows 26% Objective Response Rate With Durable Responses And Low Colitis In MSS CRC Without Liver Metastases

<ul>
<li>Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to &gt;2.5 years &nbsp;</li>
<li>IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months 
<ul>
<li>Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months</li>
<li>Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS of 8.5 months &nbsp;</li>
</ul>
</li>
<li>Positive Phase 1b data and high PRAME prevalence in melanoma reinforce the basis for the ongoing SUPRAME Phase 3 trial in previously treated advanced or metastatic cutaneous melanoma, as well as the continued Phase 1b expansion in uveal melanoma &nbsp;</li>
<li>ASCO presentations further substantiate Immatics' global leadership in precision targeting of PRAME and potential of IMA203 to be the Company's first PRAME product &nbsp;</li>
</ul>

IMTX

Reported Saturday, Immatics Presents Expanded IMA203 PRAME Cell Therapy Results At ASCO: Durable Objective Responses In 91% Of Patients And Favorable Safety Profile

A new study has warned that declining childhood vaccination rates in the United States could trigger a dramatic resurgence of diseases that were eradicated years ago.
What Happened: On Sunday, former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb shared a study on X highlighting the consequences of America&#8217;s turn towards vaccine skepticism, and a policy framework that is increasingly enabling the same.
While sharing a study titled Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination, Gottlieb quotes from it, saying, &#8220;at current vaccination rates, measles may become endemic again.&#8221;
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45715155/elizabeth-warren-calls-it-textbook-corruption-once-again-asks-for-probe-into-elon-musk-cashing-in-on-trump-tariffs">Elizabeth Warren Calls It &#8216;Textbook Corruption,&#8217; Once Again Asks For Probe Into Elon Musk &#8216;Cashing In&#8217; On Trump Tariffs</a>
He highlighted the staggering projections from the study, &#8220;51.2 [million] measles cases over a 25-year period, 9.9 [million] rubella cases, 4.3 [million] poliomyelitis cases, 197 diphtheria cases, 10.3 [million] hospitalizations, and 159,200 deaths.&#8221;
The Stanford University study&#8217;s projections are based on a scenario in which vaccine uptake drops 50%, at which point it finds that measles alone could reach endemic levels within just 5 years. 
Even at current vaccination levels, the study estimates an 83% chance of measles returning to endemicity within two decades.
The study also projects 9.9 million rubella cases, 4.3 million polio cases, and nearly 11,000 instances of congenital rubella syndrome in the event of steep declines in vaccination. The forecast includes as many as 5,400 cases of paralytic polio, a disease declared eliminated in the U.S. in 1979.
These findings come amid rising anti-vaccine sentiments in the country, alongside proposed <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">policy rollbacks</a> on vaccine mandates. 
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">‘At current vaccination rates, measles may become endemic again… a US simulation model predicted 51.2M measles cases over a 25-year period, 9.9M rubella cases, 4.3M poliomyelitis cases, 197 diphtheria cases, 10.3M hospitalizations, and 159,200 deaths'<a href="https://t.co/kSDWqTRvhb">https://t.co/kSDWqTRvhb</a>
&mdash; Scott Gottlieb, MD &#x1f1fa;&#x1f1f8; (@ScottGottliebMD) <a href="https://twitter.com/ScottGottliebMD/status/1929201297674088748?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The Health and Human Services Secretary (HHS), Robert F. Kennedy Jr, has come under increasing scrutiny for spreading vaccine misinformation. 
Last week, a senior vaccine official at the FDA, Peter Marks, resigned <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">from his position</a>, while accusing Kennedy of actions that were harmful to public health.
This also comes amid extensive <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">budget and job cuts</a> at the federal healthcare department, which includes the FDA, the National Institute of Health, and the Centers for Disease Control and Prevention, which could impair the ability of these agencies to perform their tasks effectively. 
See Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714416/former-treasury-secretary-larry-summers-warns-the-dollar-is-starting-to-trade-like-a-latin-american-currency-greenback-going-from-safe-haven-to-risk-asset">Former Treasury Secretary Larry Summers Warns The Dollar Is Starting To Trade Like A Latin American Currency — Greenback Going From Safe Haven To Risk Asset?</a></li>
</ul>
Photo courtesy: Shutterstock

Health Care

51.2 Million Measles Cases, 159,200 Deaths: New Study Warns Of Surge In Preventable Diseases Amid Growing Vaccine Skepticism

<ul>
<li>BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status</li>
<li>At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data</li>
</ul>

Reported Saturday, BeOne's SEQUOIA Trial Shows BRUKINSA Plus Venetoclax Yields Deep, Durable Responses Across CLL Risk Groups Including del(17p) And TP53

Macro Economic Events

Econ #s

Economics

U.K. Manufacturing Purchasing Managers Index For May 46.4 Vs. 45.1 Est.; 45.4 Prior

Broad Arrow Auctions, a Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) company, is delighted to announce the addition of a new event on its global auction calendar—The Zoute Concours Auction, held in collaboration with Zoute Grand Prix Car Week (8-12 October 2025) in Belgium. Set for Friday, 10 October on the grounds of the beautiful Approach Golf in Knokke-Heist, a stone's throw from the beach, the single-day auction will present approximately 70 exceptional collector cars across a wide variety of categories, marques, and price points.

HGTY

Hagerty's Broad Arrow Adds Belgium Auction Featuring 70 Classic Cars at Zoute Grand Prix

<h3>Companies Reporting Before The Bell</h3>
• The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $2.43 billion. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is estimated to report quarterly earnings at $2.12 per share on revenue of $1.87 billion. 
<h3>Companies Reporting After The Bell</h3>
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $159.59 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CRDO

SAIC

Earnings Scheduled For June 2, 2025

U.S. President Donald Trump has announced the withdrawal of Jared Isaacman's nomination for the NASA administrator job due to Isaacman's "prior associations."
What Happened: "After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA," Trump said in a post on Truth Social on Saturday.
The president then went on to say that he would announce a new nominee soon, who would be more "Mission aligned, and put America First in Space," Trump said.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="361" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg" alt="" class="wp-image-934652" style="width:484px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-300x106.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-768x271.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social.jpg 1211w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
source: Truth Social
Isaacman has donated to the Democratic Party in prior elections, as the <a href="https://www.opensecrets.org/donor-lookup/results?name=Jared+Isaacman&amp;order=desc&amp;sort=D">data</a> from the non-profit organization OpenSecrets showcases the Shift4 CEO donating to a candidate from the party.&nbsp;
Why It Matters: The news comes in just days after billionaire Elon Musk's exit from the Trump administration's DOGE, or Department of Government Efficiency. The president also hosted <a href="https://www.benzinga.com/news/25/05/45707423/trump-says-he-is-having-elon-musk-over-at-the-white-house-tomorrow-for-a-press-conference-as-billion">Musk at the White House</a>.
Isaacman's withdrawal by Trump casts uncertainty over NASA's commitment to Mars exploration, something that Isaacman had <a href="https://www.benzinga.com/general/space/25/04/44730104/trumps-nasa-chief-pick-isaacman-tells-senate-we-will-prioritize-sending-american-astronauts-to-mars">doubled down on</a> in the past and is a major target for Musk's SpaceX.
SpaceX recently held a test launch for its Starship rocket from a launch site in Texas. However, the launch failed as the <a href="https://www.benzinga.com/general/space/25/05/45636692/elon-musks-mars-ambitions-face-new-setback-as-spacex-starship-test-flight-fails">rocket spun out of control </a>30 minutes into the mission after it was launched in suborbital space.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45637814/elon-musk-admits-he-spent-too-much-time-on-politics-after-tesla-sales-decline-in-multiple-regions">Elon Musk Admits He Spent &#8216;Too Much Time&#8217; On Politics After Tesla Sales Decline In Multiple Regions</a></li>
</ul>
Photo courtesy: Pandora Pictures / Shutterstock.com

SPACE

Donald Trump Withdraws Jared Isaacman's Nomination For NASA Administrator, Says New Nominee Would 'Put America First in Space'

<ul>
<li>Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation</li>
<li>Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events</li>
<li>Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer</li>
<li>Data to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of Medicine</li>
</ul>

ARVN

Reported Saturday, Arvinas and Pfizer's Vepdegestrant Demonstrates Statistically Significant 2.9-Month PFS Benefit Over Fulvestrant In ESR1-Mutant Second-Line Advanced Breast Cancer

The Trump administration has reportedly been discreetly working with&nbsp;Palantir Technologies Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) to gather personal data of American citizens from various federal agencies, sparking concerns over privacy and potential misuse of personal data.
What Happened: President Trump&#8217;s March executive order for federal data sharing is being implemented through Palantir&#8217;s product, Foundry. Although Trump has not publicly discussed this initiative, this platform is already in use by several federal agencies, including the Department of Health and Human Services as well as the Social Security Administration, <a href="https://www.nytimes.com/2025/05/30/technology/trump-palantir-data-americans.html">reported</a> The New York Times on Friday.
Foundry&#8217;s capabilities in data organization and analysis could potentially enable the merging of information from various agencies, thereby creating detailed profiles of American citizens. The Trump administration has attempted to access extensive citizen data from government databases, including bank details, student debt, medical claims, and disability status.
Palantir did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Palantir&#8217;s selection as a primary vendor for this project was reportedly influenced by the Department of Government Efficiency (DOGE), which was being overseen by&nbsp;Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO, Elon Musk.&nbsp;
Critics, including Democratic lawmakers and privacy advocates, fear that such data could be exploited for political purposes, such as policing immigrants and targeting critics.
Some Palantir employees fear the company&#8217;s association with Trump&#8217;s agenda and potential data breaches, prompting 13 former staffers to sign a letter urging it to cut ties with the administration.
SEE ALSO:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45713694/mypillow-guy-mike-lindell-reportedly-plans-to-testify-at-his-defamation-trial-i-have-nothing-to-hide-i-a" target="_blank" rel="noreferrer noopener">MyPillow Guy Mike Lindell Reportedly Plans To Testify At His Defamation Trial: &#8216;I Have Nothing To Hide. I Am A Former Crack Addict&#8217;</a>
Why It Matters: The Trump administration&#8217;s collaboration with Palantir comes on the heels of several significant developments for the company. In late May, the Department of Defense (DoD) awarded Palantir a $795 million <a href="https://www.benzinga.com/25/05/45572000/palantir-stock-is-trading-higher-thursday-whats-going-on">modification to a contract</a> for its Maven Smart System software licenses, which likely contributed to a surge in the company&#8217;s stock price.
Earlier that month, Palantir announced a <a href="https://www.benzinga.com/markets/equities/25/05/45536259/palantir-partners-with-sap-to-fuse-ontology-foundry-and-enterprise-dataceo-alex-karp-calls-it-extremely-valuable">strategic partnership</a> with enterprise software giant&nbsp;SAP SE&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>), integrating its data platforms with SAP&#8217;s enterprise solutions, a move that CEO&nbsp;Alex Karp&nbsp;described as &#8220;extremely valuable.&#8221;
Benzinga's Edge Rankings place Palantir in the 97th percentile for quality and the 3rd percentile for value, reflecting its mixed performance. Check the detailed report <a href="https://www.benzinga.com/quote/PLTR">here</a>.&nbsp;
The shares of Palantir climbed 7.73% to close at 131.78 on Friday. On a year-to-date basis, it surged 75.26%.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/cannabis/25/06/45714198/elon-musks-kekius-maximus-gameplay-sends-these-namesake-coins-surging" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s &#8216;Kekius Maximus&#8217; Gameplay Sends These Namesake Coins Surging</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

PLTR

TSLA

Trump Administration Silently Employs Palantir To Gather Personal Data Of Each American, Raising Privacy, Data Misuse Concerns: Report

<ul>
<li>Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p&lt;0.0001)</li>
<li>Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo&nbsp;&nbsp;</li>
<li>Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine</li>
<li>Regulatory applications have been submitted in the United States and European Union</li>
</ul>

REGN

Reported Saturday, Regeneron's Libtayo Demonstrates Practice-Changing Results In Adjuvant High-Risk Cutaneous Squamous Cell Carcinoma With 87% Two-Year Disease-Free Survival

<ul>
<li>The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone –</li>
<li>The PIK3CA mutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis –</li>
<li>New data are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine</li>
</ul>

RHHBF

RHHBY

Reported Saturday, Genentech's Itovebi-Based Regimen Cuts Risk Of Death By Over 30% In PIK3CA-Mutated HR-Positive, HER2-Negative Advanced Breast Cancer, Phase III INAVO120 Data Show

President Donald Trump&#8216;s artificial intelligence advisor, David Sacks, criticized former President Barack Obama&#8216;s recent warnings <a href="https://www.benzinga.com/markets/25/05/45486440/david-sacks-hails-trumps-ai-strategy-in-middle-east-as-power-move-over-china-openai-ceo-sam-altman-backs-him-sorry-naive-people-are-giving-you-grief">about AI-driven job displacement</a>, characterizing them as part of a coordinated &#8220;influence operation&#8221; designed to advance &#8220;Global AI Governance&#8221; initiatives.
What Happened: In a series of posts on X, Sacks warned Republicans against accepting Obama&#8217;s &#8220;hyperbolic and unproven claims about AI job loss,&#8221; describing them as ammunition for what he termed a &#8220;massive power grab by the bureaucratic state and globalist institutions.&#8221;
The crypto czar specifically targeted &#8220;Effective Altruist&#8221; billionaires with histories of funding left-wing causes and opposing Trump.
Sacks responded to Andreessen Horowitz general partner Martin Casado, who praised coverage of Open Philanthropy&#8217;s alleged astroturfing campaign to regulate AI compute resources.
&#8220;There is much much more going on that is either unknown or chronically underdiscussed,&#8221; Casado noted, highlighting what he characterized as coordinated efforts to restrict AI development.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Republicans should understand that when Obama retweets hyperbolic and unproven claims about AI job loss, it's not an accident, it's part of an influence operation. The goal: to further "Global AI Governance," a massive power grab by the bureaucratic state and globalist… <a href="https://t.co/1cURrzzSL5">https://t.co/1cURrzzSL5</a>
&mdash; David Sacks (@DavidSacks) <a href="https://twitter.com/DavidSacks/status/1929276589566562358?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Sacks emphasized the fundamental ideological divide, stating these actors &#8220;fundamentally believe in empowering government to the maximum.&#8221; He warned that &#8220;the single greatest dystopian risk associated with AI is the risk that government uses it to control all of us,&#8221; potentially creating an &#8220;Orwellian future where AI is controlled by the government.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/cannabis/25/06/45713895/bitcoin-ethereum-dogecoin-hold-steady-amid-us-china-trade-war-tensions-analyst-foresees-big-party-if-btc-reclaims-106000" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Hold Steady Amid US-China Trade War Tensions: Analyst Foresees ‘Big Party' If BTC Reclaims $106,000</a>
Why It Matters: This pivot follows what industry observers call the &#8220;DeepSeek moment,&#8221; when China&#8217;s breakthrough AI model demonstrated significant capabilities, challenging Western assumptions about Chinese AI development. 
The controversy highlights tensions between rapid AI advancement and governance frameworks. Hedge fund manager Paul Tudor Jones recently warned that <a href="https://www.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous">leading AI modelers believe there&#8217;s a 10% chance</a> AI could &#8220;kill 50% of humanity&#8221; within 20 years, yet security spending remains minimal compared to $250 billion in development investments by major tech companies.
Sacks concluded his analysis by warning that &#8220;WokeAI + Global AI Governance = the most Orwellian future imaginable,&#8221; positioning this combination as the ultimate goal of Effective Altruist organizations seeking expanded regulatory control over AI development and deployment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45714095/chamath-palihapitiya-calls-tesla-an-obvious-win-says-robotaxi-alphabets-waymo-will-overtake-uber-and-lyft" target="_blank" rel="noreferrer noopener">Chamath Palihapitiya Calls Tesla An ‘Obvious Win,' Says Robotaxi, Alphabet's Waymo Will Overtake Uber And Lyft</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Tapati Rinchumrus on Shutterstock.com

Obama's AI Job Loss Warnings Aren't Accidental, Says David Sacks: They're Fueling A Global Power Grab And 'The Most Orwellian Future Imaginable'

<ul>
<li>TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial</li>
<li>The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer</li>
<li>Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology</li>
</ul>

NVCR

ZLAB

Reported Sunday, Zai Lab And Novocure Announce PANOVA-3 Results: TTFields Therapy Achieves Median OS Of 16.2 Months With Significant Gains In Quality Of Life And Pain Control

Press Releases

Discovery Lithium Announces Non-Brokered Private Placement Financing

Discovery Lithium Inc. Closes Acquisition of the Eagle Lake and Whitefish Lake Mining Claims in Northwestern Ontario

Discovery Lithium Announces Closing of Private Placement Financing

Discovery Lithium Inc. Announces Results of the 2024 Fall Exploration Program in Eeyou Istchee James Bay Region and Identification of LCT Pegmatite Geochemical Signature on Cirrus East and Bruce Lake Properties

Comments

Silk Energy

Notizie

Ultime notizie per Silk Energy (OTC:SLKEF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO